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Mitochondrial cardiomyopathies: how to identify
candidate pathogenic mutations by mitochondrial DNA
sequencing, MITOMASTER and phylogeny
Michael V Zaragoza*,1,2, Martin C Brandon1, Marta Diegoli3, Eloisa Arbustini3 and Douglas C Wallace*,1,4
Pathogenic mitochondrial DNA (mtDNA) mutations leading to mitochondrial dysfunction can cause cardiomyopathy and heart
failure. Owing to a high mutation rate, mtDNA defects may occur at any nucleotide in its 16569bp sequence. Complete mtDNA
sequencing may detect pathogenic mutations, which can be difﬁcult to interpret because of normal ethnic/geographic-associated
haplogroup variation. Our goal is to show how to identify candidate mtDNA mutations by sorting out polymorphisms using readily
available online tools. The purpose of this approach is to help investigators in prioritizing mtDNA variants for functional analysis
to establish pathogenicity. We analyzed complete mtDNA sequences from 29 Italian patients with mitochondrial cardiomyopathy
or suspected disease. Using MITOMASTER and PhyloTree, we characterized 593 substitution variants by haplogroup and allele
frequencies to identify all novel, non-haplogroup-associated variants. MITOMASTER permitted determination of each variant’s
location, amino acid change and evolutionary conservation. We found that 98% of variants were common or rare, haplogroup-
associated variants, and thus unlikely to be primary cause in 80% of cases. Six variants were novel, non-haplogroup variants and
thus possible contributors to disease etiology. Two with the greatest pathogenic potential were heteroplasmic, nonsynonymous
variants: m.15132T4Ci nMT-CYB for a patient with hypertrophic dilated cardiomyopathy and m.6570G4Ti nMT-CO1 for a
patient with myopathy. In summary, we have used our automated information system, MITOMASTER, to make a preliminary
distinction between normal mtDNA variation and pathogenic mutations in patient samples; this fast and easy approach allowed
us to select the variants for traditional analysis to establish pathogenicity.
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INTRODUCTION
Mitochondrial diseases result from abnormalities in the mitochon-
drion, the essential organelle that provides energy in the form of ATP
for normal heart function.1 Mitochondria are dynamic organelles that
number from several to hundreds per cell with each mitochondrion
containing multiple copies of mitochondrial DNA (mtDNA). Normal
mitochondrial function relies on two types of inheritance: maternal
inheritance of circular mtDNA sequences and biparental inheritance
of nuclear DNA (nDNA) that has over 1000 genes for mitochondrial
homeostasis. Consequently, mitochondrial dysfunction because of
mtDNA defects or nDNA mutations can result in disease with
cardiomyopathy and heart failure as the major features.2
mtDNA is the circular, 16569 base sequence with 37 genes that
encode for 13 proteins, 22 transfer RNAs (tRNAs) and 2 ribosomal
RNAs.3 Heteroplasmy describes the state of a mixture of normal and
mutant copies of mtDNA. Depending on the timing of origin, location
and segregation of mutant mtDNA, an individual may have different
ratios of mutant and normal mtDNA distributed amongst different
tissues or organs that result in disease.4
Owing to these genetic factors, mitochondrial diseases leading
to myocardial disease have much clinical heterogeneity in age of
presentation and severity of symptoms.5 Cardiac features include
concentric ventricular hypertrophy, dilated cardiomyopathy (DCM)
and congestive heart failure.6–8 Cardiac conduction features include
atrioventricular and bundle branch blocks.9 When mitochondrial
disease primarily affects only the heart, hypertrophic cardiomyopathy
(HCM) or dilated mitochondrial cardiomyopathies may be clinically
indistinguishable from other cardiomyopathies.6,7,10 Diagnosis may be
difﬁcult requiring cardiac tissue for diagnosis; histopathological
features include changes in mitochondrial shape or number, histo-
chemical defects and abnormities in oxidative phosphorylation
(OXPHOS) enzyme activities.5
Diagnosis of mitochondrial cardiomyopathies may be achieved by
mtDNA sequence analysis for known pathogenic mtDNA mutations.
For example, testing may be carried out for the m.3243A4Gm u t a t i o n
in the tRNA leucine gene (MT-TL1) associated with MELAS (mito-
chondrial myopathy, encephalopathy, lactic acidosis and stroke).11
The m.3243A4G mutation may also lead to severe, concentric
HCM or DCM presenting in infancy or childhood.10,12 Adults with
m.3243A4G also may present with cardiomyopathy and progressive
heart failure with extracardiac features of mitochondrial disease
including deafness and diabetes.13,14
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www.nature.com/ejhgA newly arising pathogenic mtDNA mutationwill be heteroplasmic.
As the percentage of mutant mtDNAs increases, the severity
of the clinical phenotype at each percentage mutation will
depend on the severity of the biochemical defect caused by the
mutation. Severe mtDNA mutations will result in reproductive
failure while still heteroplasmic. Hence, surviving patients with
the mutation will be heteroplasmic. By contrast, milder mtDNA
mutations may not cause clinical symptoms severe enough to affect
reproduction until they reach homoplasmy. These later mutations
have proven difﬁcult to distinguish from neutral or adaptive
polymorphisms.
It is now standard-of-care to sequence the mtDNAs of patients with
complex diseases, such as cardiomyopathy associated with mito-
chondrial dysfunction.6–8,15–17 The mtDNAs of over 500 patients
with HCM or DCM patients have already been sequenced and the
m t D N Av a r i a n t st h a td i f f e rf r o mar e f e r e n c es e q u e n c eh a v eb e e n
compared with small samples of ‘control’ cases. Those variants
observed in the patient mtDNAs but not in the study controls have
been considered to be potential disease causing mutations. Over 1000
variants have been reported in various cardiomyopathy cases, which
encompass 200 different sequence variants.6–8,15–17
However, population genetic studies have showed that the ‘normal’
mtDNA sequence variation is very high. This is the result of ancient
polymorphisms associated with distinct ethnic and/or geographic-
associated maternal lineages, known as mtDNA haplogroups.18
Distinctive haplogroup lineages are descendent from a single founding
maternal ancestor mtDNAs resulting in a discrete branch of the
mtDNA phylogenetic tree which shares the variants of the founding
mtDNA.19–22 Therefore, if a patient is from a rare mtDNA haplo-
group, then it is unlikely the control samples used in that study will
also include a mtDNA from that haplogroup. Hence, many of the
haplogroup-associated normal variants will be interpreted as poten-
tially pathogenic.
This complexity can in part be resolved by comparing the mtDNA
sequence variants of a patient with those of a large database of mtDNA
sequences that have been delineated by haplogroup. If the database
was exhaustive, then most of haplogroup-associated variants would be
represented within the database, at frequencies consistent with the
haplogroup distribution within the population. Therefore, variants
associated with speciﬁc populations will be both routinely linked to
other variants associated with that same haplogroup and will also be
present at a signiﬁcant frequency within the overall population of
mtDNA sequences.
At the other extreme, a recently arising pathogenic variant
will not be repeatedly linked to the same array of mtDNA
variants and will be very rarely in the overall population, as it is
continually being removed by selection. Therefore, novel mtDNA
variants or one found very rarely in the population have a
greater probability of being pathogenic. If the variant also affects a
functionally important mitochondrial function and is heteroplasmic,
this further increases the likelihood that the mutation is contributing
to the disease.21
On the basis of this logic, we have developed a database of several
thousand mtDNA sequences that encompasses much of the global
mtDNA variation. In addition, we have developed a computer
program, MITOMASTER,23 which will analyze a patient mtDNA
sequence based on its deviations from a master reference
sequence and then use this list of variants to deduce the
patient’s haplogroup. The variants are then compared with all other
mtDNAs in that haplogroup and the common haplogroup
variants identiﬁed. The frequency of each variant is also calculated.
Rare, non-haplogroup-associated variants are then analyzed for the
gene affected, sequence conservation, and functional consequences
permitting assessment of the potential pathogenicity of the variant. To
test the capacity of this system to help assess the pathogenic potential
of mtDNA mutations, we now apply our MITOMASTER analysis
system to a set of 29 mtDNA sequences from patients with mitochon-
drial cardiomyopathy and other mitochondrial clinical phenotypes.
The systematic approach allowed us to prioritize mtDNA sequence
variants for functional analysis to establish pathogenicity.
METHODS
Study cohort
We evaluated 29 patients referred to Dr Eloisa Arbustini at the Centre for
Inherited Cardiovascular Diseases (CICD) in Pavia, Italy. We obtained
informed written consent of all participants in accordance with the IRCCS
Foundation Policlinico San Matteo in Pavia and with the University of
California (UCI), Irvine for de-identiﬁed DNA samples. This included 21
patients with highly likely mitochondrial cardiomyopathy and 8 suspected of
mitochondrial disease as revealed by clinical, biochemical and histopathological
ﬁndings.8
Criteria for suspecting matrilineal mitochondrial cardiomyopathy included
clinical screening and pedigree evaluation with exclusion of families with male
to offspring transmission of the disease; cardiac imaging with left ventricular
(LV) dilated hypokinetic phenotypes and concentric LV hypertrophy early in
the course of disease (‘hypertrophic-dilated cardiomyopathies’); stable or
recurrent lactic academia; clinical traits of mtDNA-related diseases (4sCPK,
myopathy, encephalomyopathies, palpebral ptosis and so on) in the proband
and in maternal relatives); identiﬁcation of potentially pathologic mtDNA
variants by whole mtDNA sequencing; when possible, preliminary assessment
for homoplasmy/heteroplasmy of mtDNA variants by RFLP or Q-PCR in
endomyocardial biopsies (EMB) compared with blood; mitochondrial prolif-
eration and abnormal morphology in EMB samples; and loss of COX activity
in the myocardial samples.8
Table 1 shows the major clinical features for all 29 cases; 19 singleton and 10
familial cases based on pedigree analysis and echocardiography of family
members. Case 1 was from previously reported HCM family with an MYH7
mutation and possible mtDNA mutation m.9957T4C.24
Sanger sequencing of mtDNA
We extracted genomic DNA from blood except for case 7 in which we used
heart tissue. It should be noted that severely deleterious mtDNA mutations that
cause biochemical defects while heteroplasmic can be selectively lost from
blood, even though they are present in post-mitotic tissues. Hence, analysis of
blood mtDNAs results in the selective analysis of intermediate severity mtDNA
mutations.
At the CICD, we ampliﬁed the 16.5kb mtDNA using 59 PCR primer pairs
and then sequenced the fragments by BigDye Terminator (Applied Biosystems
Inc, Foster City, CA, USA) using 108 primers on an ABI 3730xl sequencer.
At UCI, we resequenced the mtDNA for all cases to ﬁll in gaps and conﬁrm
mutations. We used a similar protocol except for ampliﬁcation by long-range
PCR using eight primer pairs and then sequenced using 47 primers. Primer
sequences are available on request.
Sequence analysis using MITOMASTER
We assembled the data for each case using Sequencher 4.7 software (Gene
Codes, Ann Arbor, MI, USA) in comparison with the mtDNA reference,
the revised Cambridge Reference Sequence (rCRS; NC_012920)25 which is
haplogroup H2a2a.
We evaluated the mtDNA contig using MITOMASTER, a new query system
to interpret genetic variation found in mtDNA sequences.23 For each case, we
uploaded the complete mtDNA sequence into MITOMASTER to ﬁnd all
mtDNA variants, their gene location and evolutionary conservation. We used
MITOMASTER and PhyloTree, build 5 Van Oven et al22 to deﬁne the mtDNA
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mtDNA sequences from NCBI GenBank. This allowed us to obtain allele
frequencies for eachvariant. We conﬁrmed and updated allele frequencies using
analysis of Pereira et al26 based on 5140 mtDNA GenBank sequences.
Identiﬁcation of potential mtDNA mutations
Using MITOMASTER, each patient mtDNA sequence was compared with the
rCRS and all deviant nucleotides identiﬁed. The array of sequence variants was
used to determine the patient’s haplogroup. The haplogroup-associated
variants were identiﬁed and the population frequency of each nucleotide
sequence variant was calculated relative to the MITOMASTER and Pereira
et al26 databases. To identify rare variants, we arbitrarily deﬁned variants with
allele frequencies o0.5% as rare and those with frequencies Z0.5% as
common, similar to cutoff used for nDNA variation.27
Novel and rare variants were further evaluated for their potential patho-
genicity based on the gene affected, the conservation of the altered nucleotide,
the predicted amino acid (AA) change if the variant occurred within a
polypeptide gene and the conservation index (CI) of the altered amino acid,
and the presence of heteroplasmy.6–8,13,15–17,21,23
Statistical analysis
We used JMP 7.0 (SAS Institute, Cary, NC, USA) for w2-analysis. We considered
Po0.05 as a signiﬁcant difference.
RESULTS
mtDNA sequence variants detected by Sanger sequencing relative to
rCRS
For the 29 mtDNA sequences, we observed 662 mtDNA variants
compared with the rCRS (Supplementary Table). We excluded 66
highly polymorphic mtDNA variants previously described in the
mtDNA control region at positions: 303–315, 522–523, 574, 16180–
16193 and 16519.22,28 We excluded three known variants because of
insertion or deletion of a single nucleotide (indels), as allele frequen-
cies were not available. The indels included m.960delC in 12S rRNA
(case 11) and two non-coding variants m.44insC (case 18) and
m.498delC (case 13).28 We focused on the remaining 593 total
mtDNA substitution variants (Table 1) that included 270 different
mtDNA variants, as multiple variants were found in more than one
patient’s mtDNA.
Table 1 Clinical features and sequencing results for 29 Italian patients with mitochondrial cardiomyopathy (1–21) or suspected mitochondrial
disease (NonCM1-8)
By variant haplogroup By variant frequency
Case no Age a Sex Clinical information/follow-up Haplogroupb Total variantsc Associated Non Com Rare Novel
16 0 Y e a r s F H C M -DCM familial, HF, heart Tx N1b1c 33 32 1 21 12 0
24 3 Y e a r s F H C M -DCM, myopathy, LBBB/living H 14 12 2 10 2 2
3 16 Years M HCM/living HV0 14 12 2 12 1 1
4 18 Years M Hypertrophic DCM and MR/living H2 10 9 1 8 1 1
5 29 Years M SCD, HF, myopathy U8a1a 30 29 1 20 9 1
6 61 Years F DCM, diabetes, hearing loss V6 17 16 1 15 1 1
7 1 Month F HCM familial/died as an infant HV4a 17 16 1 11 6 0
8 34 Years M HCM familial, consanguinity H2 15 14 1 12 3 0
9 1 Year M HCM, severe/died H1c3 13 13 0 12 1 0
10 13 Years M HCM and hearing loss H2 10 10 0 9 1 0
11 40 Years M HCM familial and myopathy H2 10 10 0 10 0 0
12 63 Years F HCM H1 11 9 2 9 2 0
13 1 Year M DCM severe K1c1 32 32 0 31 1 0
14 12 Years F DCM familial X1a 25 24 1 21 4 0
15 26 Years M DCM and LHON U5a1 25 24 1 23 1 1
16 30 Years F DCM and SCD of sister H33 9 8 1 6 3 0
17 40 Years M DCM familial J1c 29 29 0 26 3 0
18 45 Years M DCM/died at age 48 years T2c1a 36 34 2 29 6 1
19 45 Years F DCM and atrial ﬁbrillation/living H3 7 7 0 7 0 0
20 45 Years F DCM familial and AV block T2d 39 37 2 31 5 3
21 28 Years F HCM familial H2 12 12 0 9 3 0
NonCM1 15 Years M LHON, RBBB/living, ECHO nl U5a2a 29 26 3 26 2 1
NonCM2 40 Years F Myopathy familial, ECHO nl H6a1 13 13 0 11 2 0
NonCM3 42 Years M LHON, ECHO nl W1 31 31 0 30 0 1
NonCM4 18 Years F Ptosis familial/living, ECHO nl H13a2b1 11 10 1 9 1 1
NonCM5 55 Years F Neuromuscular sx, ECHO nl M1a1 39 37 2 37 2 0
NonCM6 26 Years F LHON, ECHO nl H4a 16 13 3 13 2 1
NonCM7 62 Years M Lipomatosis, ECHO nl H13a2b1 13 12 1 10 2 1
NonCM8 32 Years M Myopathy, ECHO nl/declined by patient J2b1 33 32 1 30 2 1
Total 593 563 30 498 78 17
Abbreviations: AV, atrioventricular; Com, common variants; DCM, dilated cardiomyopathy; ECHO nl, echocardiograms normal; F, female; HCM, hypertrophic cardiomyopathy; heart Tx, heart
transplant; HF, heart failure; LBBB/RBBB, left/right bundle branch block; LHON, Leber’s hereditary optic neuropathy; M, male; MR, mental retardation; SCD, sudden cardiac death; sx, symptoms.
aAge of proband at last clinical evaluation.
bHaplogroup was determined by MITOMASTER and PhyloTree.22,23
cThe total number of mitochondrial DNA variants was obtained by comparing the sequence to NCBI reference (NC_012920). The variants were categorized ‘by haplogroup’ as ‘associated,’ variants
that deﬁned the speciﬁc haplogroup motif compared with rCRS haplogroup (H2a2a) or deﬁned other haplogroups or as ‘non,’ non-motif associated variants. The variants also were categorized ‘by
frequency’ based on allele frequencies (AF) for common variants with AF 40.5%; rare variants (rare) with AF o0.5% and novel variants (Novel) with AF¼0. Case 1 was a patient from a previously
reported HCM family with MYH7 mutation.24 The shaded rows note the six cases with potential mitochondrial DNA mutations identiﬁed in this study.
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variants only 17 of which were novel
In the ﬁrst analysis, the 593 substitution variants were analyzed for
those that were haplogroup associated. This revealed that 563 (95%)
have been associated with various haplogroups, encompassing a total
of 240 different variants (Table 1; Supplementary Table). This left 30
variants as ‘non-haplogroup associated.’ On average, there was one
‘non-haplogroup-associated’ variant per case, ranging from zero to
three variants. In nine cases, all mtDNA variants proved to be
haplogroup motifs and their mtDNAs were not analyzed further.
In the second analysis, all variants relative to the rCRS were analyzed
for their frequency in the MITOMASTER database. Of the 593 mtDNA
variants, 498 (84%) were present at a frequency Z0.5%, 78 (13%) were
rare (o0.5%) and 17 (3%) were novel (Table 1; Supplementary Table).
On the basis of allele frequencies of the 270 different variants, 176
(65%) were common, 77 (29%) rare and 17 (6%) novel. Criteria based
on allele frequency that excluded all common and rare variants was
more stringent than the haplogroup criteria; 94% of the variants were
excluded based on frequency, whereas 89% were excluded based on
haplogroup criteria (w2¼3.9, df¼1, P¼0.047).
Six novel, non-haplogroup variants identiﬁed as potential mtDNA
mutations
We excluded all haplogroup-associated variants and common or rare
variants including m.513G4Ca n dm . 9 6 1 4 A 4T, two novel variants
that were haplogroup-associated variants. The conﬂicting classiﬁca-
tions of these two variants were not surprising, as the mtDNA arrays
that comprise MITOMASTER and PhyloTree were not completely
identical. Further analysis showed that variants m.513G4Ca n d
m.9614A4T were not likely to be disease-causing mutations;
m.513G4C was a non-coding variant and recurrent in multiple
haplogroups in PhyloTree, whereas m.9614A4T was located in the
COIII coding region but resulted in a synonymous AA change.
We then evaluated the 15 remaining novel variants as possible
mutations (Table 2) based on the gene affected, sequence conservation,
polypeptide amino acid substitution and conservation, and heteroplasmy.
We detected heteroplasmy for 8 of 593 variants. In all, 4 were among the
15 novel, non-haplogroup-associated variants (Table 2).
All 15 novel, non-haplogroup-associated variants were mRNA-
coding variants, of which, 10 variants involved highly conserved
positions (CI Z67%). In addition, 6 of the 15 novel, non-hap-
logroup-associated variants were nonsynonymous variants and 9
were synonymous variants. We eliminated the nine synonymous
variants and focused on the six nonsynonymous variants as a potential
mutation in six different cases. Therefore, 23 of 29 cases (79%) lacked
potential mtDNA substitution mutations.
The six nonsynonymous variants included m.15132T4C, MT-CYB
(p.M129T) in case 2; m.15324C4T, MT-CYB (p.A193V) in case 3;
m.11069A4G, MT-ND4 (p.I104V) in case4; m.15222A4G, MT-CYB
(p.D159G) in NonCM1; m.8954T4C, MT-ATP6 (p.I143T) in NonCM6
and m.6570G4T, MT-CO1 (p.A223S) in NonCM8 (Table 2; Figure 1).
Of these six variants, three were heteroplasmic and three altered amino
acids that are highly conserved (CIZ67%; Table 2). Two of the six
variants had overlap; that is, two variants altered conserved amino acids
a n da l s ow e r eh e t e r o p l a s m i c .W ec o n s i d e r e dt h e s et w ov a r i a n t s ,
m.15132T4C, MT-CYB (p.M129T) in case 2 and m.6570G4T,
MT-CO1 (p.A223S) in NonCM8, to have the greatest potential for
being pathogenic mutations. For case 2 and NonCM8, a matrilineal
inheritance pattern for mitochondrial disease was supported or
suggested by pedigree analysis and clinical screening (Table 2, Figure 2).
Molecular testing is being offered currently to available family members.
DISCUSSION
Approach to identify potential mtDNA mutations from normal
variation
The goal of this study was to evaluate our MITOMASTER strategy to
identify potentially pathogenic mtDNA mutations within patient
mtDNA sequences. Of particular relevance was to test the effectiveness
of our system for distinguishing between haplogroup variants and
pathogenic mutations (Figure 3).23,29,30
This approach was ﬁrst successfully used to identify the pathogenic
mtDNA mutation that caused Leber’s hereditary optic neuropathy
Table 2 Fifteen novel, non-haplogroup-associated mitochondrial DNA variants
Location/effect Variant Gene AA change CI Heteroplasmy a Haplogroup Case no. Matrilineal inheritance of mitochondrial diseaseb
mRNA/Nonsyn m.15132T4C MT-CYB p.M129T 0.82 + H 2 Suggested by FH of early stroke, DM and CMP (?)
m.15324C4T MT-CYB p.A193V 0.46   HV0 3 None
m.11069A4G MT-ND4 p.I104V 0.36   H2 4 None
m.15222A4G MT-CYB p.D159G 0.36 + U5a2a NonCM1 None
m.8954T4C MT-ATP6 p.I143T 0.77   H4a NonCM6 Unknown
m.6570G4T MT-CO1 p.A223S 0.92 + J2b1 NonCM8 Present—maternal myopathy
mRNA/Synon m.12759C4T MT-ND5 Silent 0.97   H2
m.4053A4G MT-ND1 Silent 0.08   U8a1a 5
m.11920C4T MT-ND4 Silent 0.87   V6 6
m.7792C4T MT-CO2 Silent 1.00   U5a1 15
m.9980A4G MT-CO3 Silent 1.00   T2c1a 18
m.7295A4G MT-CO1 Silent 0.97   T2d 20
m.9854T4G MT-CO3 Silent 0.28 + T2d 20
m.8266A4G MT-CO2 Silent 0.67   H13a2b1 NonCM4
m.13575C4T MT-ND5 Silent 0.95   H13a2b1 NonCM7
Abbreviations: AA, amino acid; CI, conservation index; CMP (?), questionable diagnosis of cardiomyopathy; DM, diabetes mellitus; Nonsyn, nonsynonymous; Synon, synonymous.
aThe presence (+) or ( ) absence of heteroplasmy detected by Sanger sequencing are provided.
bInheritance based on the results of pedigree analysis and clinical screening by echocardiography of available family members; pedigrees of Case 2 and NonCM8 are shown in Figure 2.
The variants with the greatest pathogenic potential are in bold.
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European Journal of Human GeneticsFigure 1 Six novel, non-haplogroup variants as potential pathogenic mtDNA mutations. Shown are chromatograms for six potential mtDNA mutations
m.15132T4C, MT-CYB (p.M129T) in case 2; m.15324C4T, MT-CYB (p.A193V) in case 3; m.11069A4G, MT-ND4 (p.I104V) in case4; m.15222A4G,
MT-CYB (p.D159G) in NonCM1; m.8954T4Ci nMT-ATP6 (p.I143T) in NonCM6; m.6570G4T, MT-CO1 (p.A223S) in NonCM8. Heteroplasmy was detected
in three, that is, case 2, NonCM1 and NonCM8.
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Figure 2 Pedigree and clinical features for two cases with novel, potential mtDNA mutations: case 2 (m.15132T4C, MT-CYB) and NonCM8 (m.6570G4T,
MT-CO1). Pedigree analysis and clinical screening by echocardiography suggested (case 2) or supported (NonCM8) matrilineal inheritance of mitochondrial
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European Journal of Human Genetics(LHON) and dystonia in a Hispanic family.29,31 Complete mtDNA
sequencing of an affected family member revealed 40 variants
compared with reference sequence (step 1). Phylogenetic analysis
revealed that the patient’s mtDNA belonged to native American
haplogroup D, permitting exclusion of haplogroup-associated variants
including the previously unreported variant m.2092C4T (step 2).
Additional variants were excluded by their being reported in the
literature at ‘signiﬁcant polymorphism frequencies’ (step 3). One
novel, non-haplogroup variant remained, m.14459G4A in NADH
dehydrogenase subunit 6 (MT-ND6). This variant altered a moder-
ately conserved AA in the ND6 polypeptide. Detection of hetero-
plasmy provided further support of m.14459G4A as a potential
mutation (step 4).
Functional evidence of pathogenicity came later from transmito-
chondrial cybrid studies of m.14459G4A, which revealed an
associated OXPHOS complex I defect.32 The results conﬁrmed
m.14459G4A as a mutation, and a general approach to ﬁnd potential
mtDNA mutations was described.
In this study, we applied this approach to a large number of mtDNA
sequences from patients with cardiomyopathy or another potential
mitochondrial disease phenotype. These patient sequences were
compared with thousands of mtDNA sequences using our automated
analysis system, MITOMASTER. The approach used two additional
factors, haplogroup and allele frequencies, along with standard criteria
to evaluate the long list of mtDNA variants detected in molecular
studies on cardiomyopathy.6–8,15–17 To access large numbers of
reference mtDNAs, we used online resources such as GenBank.
Using this system, we were able to eliminate 98% of the 270 different
variants and excluded 79% of the cases (23 of 29).
Analysis of published mtDNA variants is another application using
this system. We tested the approach in identifying the conﬁrmed
m.14459G4A mutation among the 40 variants of the LHON
patient.31 Using the approach, the majority of the variants were
excluded as haplogroup-associated variants including D1 haplogroup
variants. The m.14459G4A mutation was the only candidate muta-
tion left after analysis of the non-haplogroup variants using allele
frequencies and standard criteria. We conducted example runs with
published mtDNA variants not yet conﬁrmed and found evidence for
erroneous classiﬁcations of haplogroup-associated variants as muta-
tions. We believe that this approach may be used to identify potential
mutations among the 4200mtDNA variants reported in cardio-
myopathy patients;6–8,15–17 research studies may then be concentrated
for validation of these selected variants.
We emphasize that the approach in this study was presented to
facilitate the selection of potential mtDNA mutations. Functional
analysis, clinical evaluations, pedigree analysis, family screening and
follow-up are critical in the assessment of potential mtDNA
mutations.1,2,5 Sub-haplogroup motifs particularly at the ends of the
haplogroup tree need careful consideration, as they may be relatively
new and rare in the population.21 It is possible that these nucleotides
contributed to disease as a primary defect or in combination with a
nDNA mutation. For example, rare variants found in the N1b1c
sub-haplogroup for case 1 may have inﬂuenced the progression of
MYH7-hypertrophic cardiomyopathy,24 unpublished results. Thus,
without additional analyses, the contribution of rare variants or
haplogroup effects to disease may be missed. Validation of this
approach will require transmitochondrial cybrid studies of the potential
mutations and sets excluded in this approach (for example,
sub-haplogroup motifs).
Potential mtDNA mutations for mitochondrial disease
By the end of our analysis, we had narrowed the potentially patho-
genic mtDNA mutations to six. These included one each in MT-CO1
(m.6570G4T), MT-ATP6 (8954T4C) and MT-ND4 (m.11069A4G)
and three in MT-CYB (m.15132T4C, m.15222A4Ga n d
m.15324C4T). These six potential mutations were not present
among the conﬁrmed mutations for mitochondrial disease in
MITOMAP or in previous studies on cardiomyopathies.6–8,15–17,28
Of the six, m.15132T4C (p.M129T) and m.6570G4T( p . A 2 2 3 S )
have the greatest potential of being pathogenic based on high evolu-
tionary conservation (CI¼0.82 and 0.92, respectively) and the detec-
tion of heteroplasmy. In addition, clinical evidence for matrilineal
inheritance of mitochondrial disease was present or suggested in the
family of case 2 and NonCM8 (Table 2; Figure 2).
The ﬁnal candidate mutations included two heteroplasmic CytB
variants: m.15132T4C for case 2 (haplogroup H) with hypertrophic
Figure 3 Approach to identify potential mtDNA mutations. Four major steps
to facilitate the selection of potential mtDNA mutations. *Rare variants
require additional analysis before exclusion.
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LHON and right bundle branch block. A third likely pathogenic
mutation was a homoplasmic MT-ATP6 variant m.8954T4C
(haplogroup H4a) for NonCM6 with LHON based also on its high
level of conservation (CI¼0.77).21
Three of the six potential mutations have been proposed previously
to be pathogenic, namely, heteroplasmic m.6570G4Tv a r i a n ti n
MT-CO1 (haplogroup J2b1; CI¼0.92) for NonCM8 with myopathy;
homoplasmic m.11069A4Gi nMT-ND4 (haplogroup H2; CI¼0.36)
for case 4 with HCM, mild DCM and mental retardation; and
homoplasmic m.15324C4Ti nMT-CYB (haplogroup HV0;
CI¼0.36) for case 3 with HCM. The m.6570G4T variant was
observed as a novel germline variant in a patient with sporadic
parathyroid adenoma.33 The 11069 and 15324 variants have been
reported in prostate cancer tissue,34 the speciﬁc haplogroups of these
patients were not provided. The m.11069A4G also was found as one
of 13 mtDNA variants in a patient with Parkinson’s disease on a
haplogroup H2 background,35 the same lineage as our patient. Taken
together with low level of conservation, it is possible that
m.11069A4Ga n dm . 1 5 3 2 4 C 4T, two ‘novel’ homoplasmic variants,
are haplogroup-associated variants and not mutations.
mtDNA sequence databases: the need for haplogroup-speciﬁc
control data
This analysis clearly demonstrates the critical need for large arrays of
good quality mtDNA sequences from normal individuals that encom-
p a s st h ef u l la r r a yo fm t D N Al i n e a g e sf r o ma r o u n dt h ew o r l d .
Furthermore, it demonstrates that the analysis of individual mtDNA
sequences from patients cannot be managed by hand, but must be
developed using automated systems such as MITOMASTER.23
Currently, the total extent of normal mtDNA variation within the
multitude of haplogroups from the various continental populations
remains unknown. Therefore, mtDNAs of several thousand will be
required from each continent to capture variants with frequencies in
the range of o0.5% and o0.1%, similar to cutoffs used for nDNA
variation.36
In summary, the approach demonstrated in this study allowed us to
ﬁnd potential mutations in patients with mitochondrial cardiomyo-
pathy. We hope this approachwill become more powerful as we obtain
more data on the depth of normal mitochondrial variation through-
out the world. As we enter the new era of low cost, high-throughput
genome sequencing, large scale sequencing efforts will hasten these
efforts. This will help us understand the role of the highly variable
mitochondrial genome in human disease.
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